See more : Shift Technologies, Inc. (SFTGQ) Income Statement Analysis – Financial Results
Complete financial analysis of Gamida Cell Ltd. (GMDA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gamida Cell Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- T-REX Acquisition Corp. (TRXA) Income Statement Analysis – Financial Results
- Guangdong Guanhao High-Tech Co., Ltd. (600433.SS) Income Statement Analysis – Financial Results
- Europlasma SA (1EZ0.MU) Income Statement Analysis – Financial Results
- Genco Corporation (GNCC) Income Statement Analysis – Financial Results
- Long Yuan Construction Group Co., Ltd. (600491.SS) Income Statement Analysis – Financial Results
Gamida Cell Ltd. (GMDA)
About Gamida Cell Ltd.
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.48M | 440.00K | 431.00K | 357.00K | 2.14M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.69M | -440.00K | -431.00K | -357.00K | -2.14M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -94.96% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 22.28M | 42.69M | 50.18M | 41.39M | 31.46M | 22.05M | 15.02M | 19.10M |
| General & Administrative | 44.58M | 19.40M | 16.98M | 12.17M | 12.09M | 11.60M | 4.47M | 4.61M |
| Selling & Marketing | 4.08M | 12.90K | 20.01K | 8.89K | 4.69K | 0.00 | 0.00 | 0.00 |
| SG&A | 48.67M | 19.40M | 16.98M | 12.17M | 12.09M | 11.60M | 4.47M | 4.61M |
| Other Expenses | -395.00K | 12.90M | 20.01M | 8.75M | 4.69M | 195.00K | -2.27M | 1.81M |
| Operating Expenses | 70.95M | 74.99M | 87.17M | 62.30M | 48.25M | 33.64M | 19.49M | 23.71M |
| Cost & Expenses | 74.43M | 74.99M | 87.17M | 62.30M | 48.25M | 33.64M | 19.49M | 23.71M |
| Interest Income | 2.73M | 4.38K | 2.63K | 236.00K | 17.15M | 1.04M | 330.00K | 163.00K |
| Interest Expense | 7.59M | 4.38M | 2.63M | 10.64M | 3.33M | 20.26M | 30.00K | 23.00K |
| Depreciation & Amortization | 2.02M | -149.55M | 431.00K | 2.63M | 19.29M | 269.00K | 162.00K | 124.00K |
| EBITDA | -70.62M | -74.55M | -86.74M | -60.57M | -28.95M | -32.60M | -20.16M | -24.48M |
| EBITDA Ratio | -3,958.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -72.64M | 74.99M | -87.17M | -62.30M | -48.25M | -33.64M | -19.49M | -23.71M |
| Operating Income Ratio | -4,071.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 9.65M | -4.38M | -2.63M | -648.00K | 13.82M | -19.22M | 479.00K | 1.04M |
| Income Before Tax | -63.00M | -79.38M | -89.79M | -72.70M | -34.42M | -52.86M | -19.01M | -22.67M |
| Income Before Tax Ratio | -3,531.17% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.00 | 74.99M | 2.63M | 3.74M | -70.00K | 70.00K | -479.00K | -1.04M |
| Net Income | -63.00M | -154.37M | -92.42M | -76.45M | -34.35M | -52.93M | -19.01M | -22.67M |
| Net Income Ratio | -3,531.17% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.57 | -2.42 | -1.56 | -1.75 | -1.17 | -10.53 | -1.06 | -1.26 |
| EPS Diluted | -0.57 | -2.42 | -1.56 | -1.75 | -1.16 | -10.53 | -1.06 | -1.26 |
| Weighted Avg Shares Out | 110.05M | 63.83M | 59.25M | 43.73M | 29.46M | 5.03M | 17.97M | 17.97M |
| Weighted Avg Shares Out (Dil) | 110.05M | 63.83M | 59.25M | 43.73M | 29.66M | 5.03M | 17.97M | 17.97M |
Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q2 2022 Results - Earnings Call Transcript
Gamida Cell Ltd. (NASDAQ:GMDA ) Q2 2022 Earnings Conference Call August 15, 2022 8:00 AM ET Company Participants Heather DiVecchia - Director of IR & Corporate Communications Julian Adams - CEO Ronit Simantov - CMO & Chief Scientific Officer Michele...
Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today provided a business update and reported financial results for the quarter ended June...
Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today provided a business update and reported financial results for the quarter ended June...
Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today provided a business update and reported financial results for the quarter ended June...
Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces dosing of the first patient in a company-sponsored Phase 1/2 study evaluating...
Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces dosing of the first patient in a company-sponsored Phase 1/2 study evaluating...
Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, today announced that the company will host a conference call and live audio...
Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted for...
Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted for...
Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted for...
Source: https://incomestatements.info
Category: Stock Reports